Deere & Company vs Revvity Inc — how do they compare? Deere & Company trades at $652.61 (market cap $175.95B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Deere & Company is far larger — about 10.4× Revvity Inc's market cap, and Deere & Company pays the higher dividend (0.99%). Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Revvity Inc for 12 Days on average.
| DE | RVTY | |
|---|---|---|
Market Cap | $175.95B | $16.98B |
Volume | 1,387,231 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $709.48 | $157.36 |
52-Week Low | $439.11 | $82.26 |
Typical Hold Time | 75 Days | 12 Days |
Enterprise Value | $229.85B | $19.30B |
Dividend Yield | 0.99% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, reflecting near-term pressure amid a broader bearish technical signal. The stock has demonstrated strong earnings momentum, beating estimates in the last three quarters, but faces headwinds from declining revenue and net income margins. Recent news highlights the company's focus on AI-driven agricultural solutions to counter cyclical downturns, while analyst consensus remains divided with a price target of $731.20 suggesting potential upside from current levels.
The outlook for DE is mixed; solid profitability metrics and consistent cash flow generation support the investment case, but cyclical exposure to agriculture equipment demand and elevated valuation ratios pose risks. Earnings growth and successful execution of technology initiatives are key catalysts for outperformance, though macroeconomic volatility could dampen near-term returns.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →